Developer docs
API playgroundTry for free, no card

Search company profiles

Breakout Labs

Full company profile

uuid0000jpg

Namestring
Breakout Labs
Legal namestring
Breakout Ventures
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Breakout Ventures (operating publicly as Breakout Labs) is a San Francisco-based early-stage venture capital firm that invests at the frontier of science-driven technology. Founded in 2013, the firm deploys capital into companies building transformative products across biotech, tech-bio, deep tech, hard tech, and chem tech sectors. Its named portfolio spans diagnostic platforms for immune-mediated diseases (Cytovale), sustainable biofabrication (Modern Meadow), in vivo gene therapy (STRM.BIO), mycelium-grown materials (EcoVative Design), AI-enabled cancer immunotherapy (Noetik), precision autoimmune therapeutics (Epana Bio), high-yield biomanufacturing (ZymoChem), and carbon dioxide-to-chemicals transformation (Twelve).

The firm operates as a classic early-stage venture capital fund. Breakout raises capital from limited partners and deploys it into portfolio companies, generating returns through fund management fees and carried interest on investment gains. The firm does not develop proprietary technology itself; its edge is operational and selection-driven, described in firm materials as "conviction from Day One" early investing, rigorous partnership focused on inflection points, and access to a catalytic network of corporates, strategic partners, and next-stage investors. The investment team is positioned as scientists and operators with technical depth and commercial fluency. Distribution is direct: the firm engages founders through its contact page, LinkedIn, Twitter, Medium, and newsletter channels.

In March 2026, Breakout closed Fund III at $114 million, continuing a decade-plus strategy of backing founders building what it describes as category-defining companies powered by science. Leadership includes co-founders Peter Thiel, Ajay Royan, Lindy Fishburne, and Jim O'Neill, alongside portfolio director Julia Moore and scientific director Hemai Parthasarathy. The firm operates with a small team of 1-10 employees from San Francisco.

Short descriptiontext

Breakout Ventures (also known as Breakout Labs) is a San Francisco-based early-stage venture capital firm investing in science-driven technology companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors, most recently closing Fund III at $114 million.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital funding, early-stage investment, scientific innovation, biotech investment, deep tech funding
Industry2 codes
1Early-Stage Venture Capital (Series A/B)
CodeFSANAAABPrimaryYes
2Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryNo
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Vehicles525990
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Breakout Labs (legally Breakout Ventures) is a venture capital firm that invests early-stage capital into founders building scientific innovation companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors. The firm provides not only capital but also operational support, technical guidance, and access to a network of corporates, strategic partners, and next-stage investors to help portfolio companies reach inflection points.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Breakout Ventures Fund III
CategoryVenture Capital Fund
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage venture firm investing in deep tech, science, and frontier technology companies. Directly comparable to Breakout given its sector focus on biotech, advanced materials, climate, and space, with a thesis-driven, conviction-led investment style.

TypeDirect peer
Description

Science-driven venture firm that creates and funds breakthrough biotechnology companies from internal ideation. Comparable to Breakout given shared focus on biotech and science innovation, though Flagship operates a more originator-heavy model.

TypeBroad incumbent
Description

Large, established venture firm with significant allocation to deep tech, biotech, and science-driven frontier technologies. Comparable given its substantial science innovation portfolio, though broader in stage and sector than Breakout.

TypeEmerging player
Description

Early-stage venture firm investing in deep tech, science, and engineering-driven founders. Comparable given shared focus on pre-seed and seed science-driven innovation, though typically earlier stage than Breakout.

TypeDirect peer
Description

Early-stage venture firm investing in transformative companies at the intersection of materials science, manufacturing, and sustainability. Comparable to Breakout given shared thesis on advanced materials and deep tech investing.

TypeDirect peer
Description

Venture fund backed by high-profile investors and focused exclusively on climate and deep tech innovation. Comparable given shared focus on transformative science companies in climate, materials, and biotech (e.g., Twelve).

TypeDirect peer
Description

Deep tech venture firm investing in early-stage companies applying computational and engineering breakthroughs to transform industries. Highly comparable given overlap in deep tech, biotech, climate, and materials thesis investing.

TypeEmerging player
Description

Venture firm founded by Bill Maris focused on science, technology, and healthcare innovation. Comparable given its sector specialization and thesis-driven early-stage investing in biotech and deep tech.

TypeEmerging player
Description

Early-stage venture firm investing in bio and engineering-driven companies at the frontier of biology. Comparable given shared focus on biotech, synbio, and science-driven founders building category-defining companies.

TypeDirect peer
Description

Long-tenured early-stage venture firm focused on science-driven companies in biotech, advanced materials, and clean energy. Comparable given its decades-long specialization in scientific innovation and similar portfolio categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment39 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breakout Labs

Venture Capitalbreakoutlabs.org

Breakout Ventures (also known as Breakout Labs) is a San Francisco-based early-stage venture capital firm investing in science-driven technology companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors, most recently closing Fund III at $114 million.

What Breakout Labs does

Breakout Ventures (operating publicly as Breakout Labs) is a San Francisco-based early-stage venture capital firm that invests at the frontier of science-driven technology. Founded in 2013, the firm deploys capital into companies building transformative products across biotech, tech-bio, deep tech, hard tech, and chem tech sectors. Its named portfolio spans diagnostic platforms for immune-mediated diseases (Cytovale), sustainable biofabrication (Modern Meadow), in vivo gene therapy (STRM.BIO), mycelium-grown materials (EcoVative Design), AI-enabled cancer immunotherapy (Noetik), precision autoimmune therapeutics (Epana Bio), high-yield biomanufacturing (ZymoChem), and carbon dioxide-to-chemicals transformation (Twelve).

The firm operates as a classic early-stage venture capital fund. Breakout raises capital from limited partners and deploys it into portfolio companies, generating returns through fund management fees and carried interest on investment gains. The firm does not develop proprietary technology itself; its edge is operational and selection-driven, described in firm materials as "conviction from Day One" early investing, rigorous partnership focused on inflection points, and access to a catalytic network of corporates, strategic partners, and next-stage investors. The investment team is positioned as scientists and operators with technical depth and commercial fluency. Distribution is direct: the firm engages founders through its contact page, LinkedIn, Twitter, Medium, and newsletter channels.

In March 2026, Breakout closed Fund III at $114 million, continuing a decade-plus strategy of backing founders building what it describes as category-defining companies powered by science. Leadership includes co-founders Peter Thiel, Ajay Royan, Lindy Fishburne, and Jim O'Neill, alongside portfolio director Julia Moore and scientific director Hemai Parthasarathy. The firm operates with a small team of 1-10 employees from San Francisco.

Breakout Labs firmographics

Firmographics
Name
Breakout Labs
Legal name
Breakout Ventures
Website
https://breakoutlabs.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Breakout Ventures (also known as Breakout Labs) is a San Francisco-based early-stage venture capital firm investing in science-driven technology companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors, most recently closing Fund III at $114 million.
Ownership category
akta.pro rank

Breakout Labs industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro primary industry
Early-Stage Venture Capital (Series A/B) (FSANAAAB)
akta.pro secondary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Venture capital funding
  • Early-stage investment
  • Scientific innovation
  • Biotech investment
  • Deep tech funding

Where Breakout Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Breakout Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels4 records

Breakout Labs product offering

Product offering

Core offering

Breakout Labs (legally Breakout Ventures) is a venture capital firm that invests early-stage capital into founders building scientific innovation companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors. The firm provides not only capital but also operational support, technical guidance, and access to a network of corporates, strategic partners, and next-stage investors to help portfolio companies reach inflection points.

Differentiator

Problem solved

Functional benefit

Products and services

  • Breakout Ventures Fund III

Companies that use Breakout Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Breakout Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Breakout Labs partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Breakout Labs competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Early-stage venture firm investing in deep tech, science, and frontier technology companies. Directly comparable to Breakout given its sector focus on biotech, advanced materials, climate, and space, with a thesis-driven, conviction-led investment style.
  • Flagship Pioneering: Science-driven venture firm that creates and funds breakthrough biotechnology companies from internal ideation. Comparable to Breakout given shared focus on biotech and science innovation, though Flagship operates a more originator-heavy model.
  • Material Impact: Early-stage venture firm investing in transformative companies at the intersection of materials science, manufacturing, and sustainability. Comparable to Breakout given shared thesis on advanced materials and deep tech investing.
  • Breakthrough Energy Ventures: Venture fund backed by high-profile investors and focused exclusively on climate and deep tech innovation. Comparable given shared focus on transformative science companies in climate, materials, and biotech (e.g., Twelve).
  • DCVC (Data Collective Venture Capital): Deep tech venture firm investing in early-stage companies applying computational and engineering breakthroughs to transform industries. Highly comparable given overlap in deep tech, biotech, climate, and materials thesis investing.
  • ARCH Venture Partners: Long-tenured early-stage venture firm focused on science-driven companies in biotech, advanced materials, and clean energy. Comparable given its decades-long specialization in scientific innovation and similar portfolio categories.

Broad incumbents

  • Khosla Ventures: Large, established venture firm with significant allocation to deep tech, biotech, and science-driven frontier technologies. Comparable given its substantial science innovation portfolio, though broader in stage and sector than Breakout.

Emerging players

  • Prelude Ventures: Early-stage venture firm investing in deep tech, science, and engineering-driven founders. Comparable given shared focus on pre-seed and seed science-driven innovation, though typically earlier stage than Breakout.
  • Section 32: Venture firm founded by Bill Maris focused on science, technology, and healthcare innovation. Comparable given its sector specialization and thesis-driven early-stage investing in biotech and deep tech.
  • Petri.bio: Early-stage venture firm investing in bio and engineering-driven companies at the frontier of biology. Comparable given shared focus on biotech, synbio, and science-driven founders building category-defining companies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Breakout Labs social profiles

Digital presence

Breakout Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breakout Labs leadership team

Management profile

Number of profiles

Profiles6 records

Breakout Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breakout Labs M&A and investment

M&A and investment

M&A

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breakout Labs

What does Breakout Labs do?

Breakout Labs (legally Breakout Ventures) is a venture capital firm that invests early-stage capital into founders building scientific innovation companies across biotech, tech-bio, deep tech, hard tech, and chem tech sectors. The firm provides not only capital but also operational support, technical guidance, and access to a network of corporates, strategic partners, and next-stage investors to help portfolio companies reach inflection points.

Is Breakout Labs a public or private company?

Breakout Labs is a private company. It is classified as unknown and is currently operating.

When was Breakout Labs founded?

Breakout Labs was founded in 2013. It employs 1 to 10 people.

Where is Breakout Labs based?

Breakout Labs is headquartered in San Francisco, United States, in the North America region.

Who are Breakout Labs's main competitors?

Direct peers on record are Lux Capital, Flagship Pioneering, Material Impact, Breakthrough Energy Ventures, DCVC (Data Collective Venture Capital) and ARCH Venture Partners. Khosla Ventures is listed as a broad incumbent. Emerging players are Prelude Ventures, Section 32 and Petri.bio.

Does Breakout Labs have an API?

No public API is recorded for Breakout Labs.

What industry is Breakout Labs in?

Breakout Labs's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebNew FlightWave Drone Delivers Stronger, Faster PerformanceFlightWave Aerospace Systems, Inc. announced its new drone designed for sustained aerial operations in high-wind, maritime, or terrestrial missions. The company also disclosed receiving an investment from Breakout Labs, the Thiel Foundation’s program supporting deep technology ventures.PR NewswireGrowing Quantum Dot Manufacturer, UbiQD, Named Breakout Labs Portfolio CompanyUbiQD, Inc., a New Mexico-based quantum dot manufacturer, has been named a portfolio company of Breakout Labs, a seed-stage fund within the Thiel Foundation, receiving $350,000 in funding to advance its luminescent solar concentrator technology and develop a greenhouse product. The investment marks Breakout Labs' first investment in New Mexico and is part of a broader initiative to support scientist-entrepreneurs in commercializing early-stage scientific discoveries. UbiQD also completed a corporate restructuring from LLC to C-corporation on October 1 and recently purchased its 9,000-square-foot headquarters in Los Alamos after securing financing from Los Alamos County via the LEDA program.Nanalyze20 Peter Thiel Backed Startups at Breakout LabsBreakout Labs, Peter Thiel's incubator, has invested in 20 startups with radical emerging technologies. The companies include projects like digital noses, antimatter propulsion, and biomimetic materials. The article argues these moonshot ideas could disrupt the future.FinSMEsBreakout Labs and NetScientific Team up to Support HealthCare and Life Sciences CompaniesBreakout Labs and NetScientific announced a strategic partnership, with NetScientific investing up to $250,000 in Breakout Labs portfolio companies. CytoVale, a diagnostics developer, is the first to receive such an investment. Breakout Labs has supported 16 companies in areas like biomedicine and clean energy.FinSMEsCytoVale Receives Investment from Breakout LabsCytoVale, a San Francisco-based mechanomics company, received an undisclosed investment from Breakout Labs, the Thiel Foundation's program. The company's microfluidic device measures over 10 biophysical cell markers at rates above 2,000 cells per second. It had previously received a $200k SBIR Award.FinSMEsPareto Biotechnologies Raises Funding from Breakout LabsPareto Biotechnologies raised undisclosed funding from Breakout Labs to develop designer molecules for fragrances and flavorings. The company plans to focus on cosmetics, flavors, and fragrances by 2015, with longer-term applications in nutraceuticals, pharmaceuticals, and industrial commodities.CNBCPeter Thiel Backs Start-up Making 3D Printed MeatBreakout Labs, Peter Thiel's biotech foundation, awarded a $350,000 grant to Modern Meadow, a Missouri start-up developing 3D printed meat and leather. The company uses animal stem cells to create tissues, aiming to reduce environmental impacts of traditional livestock. Two additional grants were given to Bell Biosystems and Entopsis.TechCrunchPeter Thiel’s Breakout Labs Funds Tissue Engineering, Nano-Engineering Projects And MoreBreakout Labs, Peter Thiel's early-stage research fund, awarded a new round of grants to three companies developing tissue engineering, regenerative medicine, and nano-engineered disease diagnostics. The fund awards between $50,000 and $350,000 while allowing grantees to retain intellectual property rights in exchange for a capped royalty. Among the funded projects, Modern Meadow is working on growing meat from stem cells in a dish as an alternative to traditional animal agriculture, with a cured meat prototype already in development.